MedTrace Logo

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

NCT07532902 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-04-16

No results posted yet for this study

Summary

The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced unresectable MTAP-deleted solid tumor cancer.

Conditions

Interventions

DRUG

BMS-986504

BMS-986504 PO daily

DRUG

Ipilimumab

Ipilimumab (1mg/kg Q6wk)

DRUG

Nivolumab

Nivolumab (360mg flat dose Q3wk)

DRUG

5-FU

are continued until disease progression or intolerance

DRUG

Leucovorin

are continued until disease progression or intolerance

DRUG

Oxaliplatin

are continued until disease progression or intolerance

DRUG

Gemcitabine

Gemcitabine are given for a maximum of 6 cycles

DRUG

Platinum

Platinum are given for a maximum of 6 cycles

Sponsors & Collaborators

Principal Investigators

  • Michael Offin, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-07
Primary Completion
2029-04-30
Completion
2029-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07532902 on ClinicalTrials.gov